In clinical trials, neither weight gain nor weight loss was consistently reported as a side effect
Understanding the pharmacokinetics of semaglutide provides insight into expected recovery timelines
For a 170-pound person, that works out to about 93 to 123 grams of the macronutrient every day
Given the substantial benefits of semaglutide and SGLT2 inhibitors, concurrent use may be considered in type 2 diabetes with chronic kidney disease. References: Mann JFE, et al
Straightforward from the start Getting started is easy 1
There is a currently ongoing clinical trial, the SEmaglutide randomized PRAgmatic (SEPRA) trial, which will compare the effects of adding Ozempic to other antidiabetic drugs, including metformin and sulfonylureas